These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 29485531)

  • 1. Sarcoid-like reactions in patients receiving modern melanoma treatment.
    Dimitriou F; Frauchiger AL; Urosevic-Maiwald M; Naegeli MC; Goldinger SM; Barysch M; Franzen D; Kamarachev J; Braun R; Dummer R; Mangana J
    Melanoma Res; 2018 Jun; 28(3):230-236. PubMed ID: 29485531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors.
    Firwana B; Ravilla R; Raval M; Hutchins L; Mahmoud F
    J Oncol Pharm Pract; 2017 Dec; 23(8):620-624. PubMed ID: 27590328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients.
    Tetzlaff MT; Nelson KC; Diab A; Staerkel GA; Nagarajan P; Torres-Cabala CA; Chasen BA; Wargo JA; Prieto VG; Amaria RN; Curry JL
    J Immunother Cancer; 2018 Feb; 6(1):14. PubMed ID: 29433571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
    Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
    J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma.
    Danlos FX; Pagès C; Baroudjian B; Vercellino L; Battistella M; Mimoun M; Jebali M; Bagot M; Tazi A; Lebbé C
    Chest; 2016 May; 149(5):e133-6. PubMed ID: 27157227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A case-control study.
    Cabanié C; Ammari S; Hans S; Pobel C; Laparra A; Danlos FX; Chanson N; Dolidon S; Seban R; Voisin AL; Pautier P; Romano-Martin P; Even C; Baldini C; Besse B; Albiges L; Boutros C; Routier E; Balleyguier C; De Montpreville VT; Champiat S; Massard C; Robert C; Marabelle A; Mateus C; Lambotte O; Le Pavec J; Michot JM
    Eur J Cancer; 2021 Oct; 156():46-59. PubMed ID: 34425404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarcoidosis related to checkpoint and BRAF/MEK inhibitors in melanoma.
    Rubio-Rivas M; Moreira C; Marcoval J
    Autoimmun Rev; 2020 Aug; 19(8):102587. PubMed ID: 32553612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation.
    Lheure C; Kramkimel N; Franck N; Laurent-Roussel S; Carlotti A; Queant A; Goldwasser F; Avril MF; Dupin N
    Dermatology; 2015; 231(4):378-84. PubMed ID: 26452227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma.
    Reddy SB; Possick JD; Kluger HM; Galan A; Han D
    J Immunother; 2017 Oct; 40(8):307-311. PubMed ID: 28737620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges in sarcoidosis and sarcoid-like reactions associated to immune checkpoint inhibitors: A narrative review apropos of a case.
    Apalla Z; Kemanetzi C; Papageorgiou C; Bobos M; Manoli M; Fotiadou C; Hatzibougias D; Boukovinas I; Stergiou E; Levva S; Lallas A; Lazaridou E
    Dermatol Ther; 2021 Jan; 34(1):e14618. PubMed ID: 33263945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis.
    Lomax AJ; McGuire HM; McNeil C; Choi CJ; Hersey P; Karikios D; Shannon K; van Hal S; Carr U; Crotty A; Gupta SK; Hollingsworth J; Kim H; Fazekas de St Groth B; McGill N
    Int J Rheum Dis; 2017 Sep; 20(9):1277-1285. PubMed ID: 28480561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical systemic sarcoid-like granulomatosis in two patients treated with BRAF and MEK inhibitors.
    Assan F; Schlemmer F; Assie JB; Mahevas M; Sustronck P; Ortonne N; Velter C; Fardet L; Zehou O
    Eur J Dermatol; 2019 Oct; 29(5):556-557. PubMed ID: 31649010
    [No Abstract]   [Full Text] [Related]  

  • 13. Granulomatous Tumoral Melanosis Associated With Pembrolizumab Therapy: A Mimicker of Disease Progression in Metastatic Melanoma.
    Woodbeck R; Metelitsa AI; Naert KA
    Am J Dermatopathol; 2018 Jul; 40(7):523-526. PubMed ID: 29924748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sarcoid-like Reaction Discovered on EBUS-TBNA of Intrathoracic Lymph Nodes During Immunotherapy for Metastatic Melanoma.
    Frohlich M; Wang H; Sakr L
    J Immunother; 2020; 43(2):75-78. PubMed ID: 31567703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy-induced exclusively cutaneous sarcoid-like reaction.
    Mazumder A; Mehrmal S; Chaudhry S
    BMJ Case Rep; 2023 Jul; 16(7):. PubMed ID: 37463781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors.
    Gkiozos I; Kopitopoulou A; Kalkanis A; Vamvakaris IN; Judson MA; Syrigos KN
    J Thorac Oncol; 2018 Aug; 13(8):1076-1082. PubMed ID: 29763666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sarcoid-like reaction in cases treated by checkpoint inhibitors.
    Paydas S
    Med Oncol; 2021 Feb; 38(3):29. PubMed ID: 33598792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.
    Goldman C; Tchack J; Robinson EM; Han SW; Moran U; Polsky D; Berman RS; Shapiro RL; Ott PA; Osman I; Zhong H; Pavlick AC; Wilson MA
    Oncology; 2017; 93(3):164-176. PubMed ID: 28601879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-induced cutaneous sarcoidosis in melanoma.
    Suárez-García C; Pérez-Gil A; Pereira-Gallardo S; Codes-Villena M; García-Escudero A; Miguel Camacho F
    Melanoma Res; 2009 Dec; 19(6):391-4. PubMed ID: 19770687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.